Vyndaqel: novel treatment for amyloid neuropathy

Pfizer has launched Vyndaqel (tafamidis) to delay peripheral neurologic impairment in patients with transthyretin familial amyloid polyneuropathy.

Vyndaqel (tafamidis) should be used in addition to standard care for transthyretin familial amyloid polyneuropathy.
Vyndaqel (tafamidis) should be used in addition to standard care for transthyretin familial amyloid polyneuropathy.


Tafamidis is a novel specific stabiliser of transthyretin. Dissociation of the transthyretin tetramer to monomers is the rate-limiting step in the pathogenesis of transthyretin familial amyloid polyneuropathy. Tafamidis binds to the tetrameric form of transthyretin, inhibiting this dissociation and slowing disease progression.1


The safety and efficacy of tafamidis 20mg once daily were evaluated in a double-blind randomised, controlled study involving 128 patients with transthyretin familial amyloid polyneuropathy with the V30M mutation and primarily stage 1 disease.1

A pre-specified intention-to-treat analysis (n=125) after 18 months of treatment showed that more patients in the tafamidis group were responders on the Neuropathy Impairment Score of the Lower Limb (NIS-LL) scale than in the placebo group, although the difference was not significant (45.3% versus 29.5%, p=0.068).1

Analysis of secondary outcome measures showed that tafamidis treatment was associated with less deterioration of neurologic function and improved nutritional status compared with placebo.1

Safety profile

Tafamidis was generally well tolerated, with urinary tract infection and diarrhoea the most commonly reported adverse effects.1


  1. Vyndaqel Summary of Product Characteristics, December 2012

View Vyndaqel drug record

Further information:  Astellas

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases